Sharda Cropchem Q2 FY27: Revenue up 13% to ₹1,052 Cr, PAT grows 23% to ₹92 Cr
Sharda Cropchem's Q2 FY27 revenue rose 13% YoY to ₹1,052 Cr, with PAT up 23% to ₹92 Cr. EBITDA grew 18% to ₹164 Cr. NAFTA and LATAM regions showed strong growth. The company maintains its FY27 revenue guidance of 10-15% and expects EBITDA margins between 18-20%. Planned capex for FY27 is ₹550-600 Cr.
The announcement details significant financial growth, including double-digit increases in revenue and profit, and reaffirms positive future outlook and guidance. This directly impacts investor perception and company valuation.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax, exceeding market expectations and maintaining positive future guidance. Growth in key regions like NAFTA and LATAM further supports the positive sentiment.
Sharda Cropchem Limited reported a robust performance for the second quarter of FY27, with revenue growing by 13% year-on-year to ₹1,052 crores. This growth was driven by increased prices, a positive forex impact, and an improved product mix, despite a volume degrowth of 5.1%. Gross margins expanded by 140 basis points to 35.9%, and EBITDA grew by 18% to ₹164 crores, resulting in an EBITDA margin of 15.6%. Profit after tax (PAT) for the quarter surged by 23% to ₹92 crores.
The company highlighted strong performance in the NAFTA region, with revenue growing by approximately 30% year-on-year, and the LATAM region also showing significant growth in agrochemical revenue, up by over 80%. Europe, while experiencing a slight moderation due to weather challenges, is expected to recover in the second half of the fiscal year.
For the first half of FY27, revenue increased by 11% to ₹2,125 crores. The agrochemical business grew by 6% to ₹1,755 crores, while the non-agrochemical business saw a substantial 40% growth to ₹371 crores. EBITDA for H1 FY27 grew by 22% to ₹343 crores, with EBITDA margins at 16.1%.
Sharda Cropchem maintained its FY27 revenue growth guidance of 10% to 15% and expects EBITDA margins to be between 18% to 20% for the full fiscal year. The company also plans a capital expenditure of ₹550 to ₹600 crores for FY27, focusing on increasing product registrations. As of September 30, 2026, the company reported a debt-free status with cash and bank liquid investments amounting to ₹846 crores. The company's ROCE stood at 25.9% and ROE at 20.1%.
What to do with a filing like this
Sharda Cropchem Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sharda Cropchem Limited. Read the original for the full detail.